

BÖLÜM 5

ATRİYAL FİBRİLASYON VE FLUTTER: SINIFLAMA, TANI VE TEDAVİ

Alp YILMAZ¹

GİRİŞ

Atriyal Fibrilasyon ve Flutter, dar QRS kompleks taşikardiler sınıfında yer alan aritmilerdir. QRS kompleksinin dar olması (0,12 sn'nin altında) normal his purkinje sistemi yoluyla ventriküllerin hızlı aktivasyonunu gösterir. Bu durumda aritmi atriyoventriküler (AV) düğüm üstünden veya içinden kaynaklanmaktadır. Yani sinüs düğümü, atriyum, AV düğüm veya bu alanların kombinasyonundan kaynaklanmış olabilir.

ATRİYAL FİBRİLASYON

Atriyal Fibrilasyon (AF) en sık tedavi edilen, koordine olmayan atriyal elektriksel aktivitenin ve inefektif atriyal kasılmanın sonucu gerçekleşen bir supraventriküler taşiaritmidir. Elektrokardiyogramda (EKG) Şekil 1'deki gibi düzensiz QRS komplekslerinin görülmesi, tutarlı P dalgalarının yokluğu ve zeminde sıklık, amplitüd ve şekilleri düzensiz f (fibrilasyon) dalgalarının olduğu işlev bozuklukları ile karakterizedir (1). EKG'de P dalgası görülmez ve testere dişi/flutter dalgaları yoktur. En az 30 saniye süren bir atak klinik için tanısalmaktadır (2). Sağlıklı bir kalp dakikada 60-100 kez kanı pompalar. AF'de ise kalp ritimlerinin düzensiz olması nedeniyle dakikada 150 defadan fazla pompalama yapabilir. AF'de atriyum düzensiz elektrik sinyallerine mekanik olarak cevap veremediğinden atriyum düzgün bir şekilde kasılmak yerine seğirmeye başlar (3). AF varlığında kalp yetmezliği (KY) ve tromboembolizm riski belirgin olarak artmaktadır ve etkilenen hastalarda yüksek mortaliteye sebep olmaktadır (4).

¹ Uzm. Dr., SBÜ İstanbul Taksim Eğitim ve Araştırma Hastanesi, Acil Tıp Kliniği
dralpymz@gmail.com

KAYNAKLAR

1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: 2001; 104(17): 2118-50.
2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines For The Diagnosis And Management Of Atrial Fibrillation. *European Heart Journal*, 2021; 42(5): 373-498.
3. Hagiwara Y, Fujita H, Oh S. L, et al. Computer-Aided Diagnosis Of Atrial Fibrillation Based On ECG Signals: A Review. *The Journal of Sciences*, 2018; 467: 99-114.
4. Pritchett E.L. Management of atrial fibrillation. *The New England Journal of Medicine*, 1992; 326(19): 1264-1271.
5. Puech P, H Latour and R Grolleau. Flutter and his limits. *Archives des Maladies du Coeur et des Vaisseaux*, 1970; 63(1): 116-144.
6. Petryszyn P, Niewinski P, Staniak A, et al. Effectiveness Of Screening For Atrial Fibrillation And Its Determinants. A Meta-Analysis. *PLoS One*, 2019; 14(3): e0213198.
7. Björck S, Palaszewski B, Friberg L, et al. Atrial fibrillation, stroke risk, and warfarin therapy revisited. *Stroke*. 2013; 44(11): 3103-3108.
8. Lip GYH, Brechin CM, Lane DA. The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Epidemiology of Atrial Fibrillation in Regions Outside North America and Europe. *Chest*. 2012; 142(6): 1489-98.
9. Shen AY-J, Contreras R, Sobnosky S, et al. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults crosssectional study. *Journal of the National Medical Association*. 2010; 102(10): 906-14.
10. Wetterslev M, Haase, N, Hassager C, et al. New- Onset Atrial Fibrillation Ğn Adult Critically Ğll Patients: A Scoping Review. *Intensive care medicine*, 2019; 45(7): 928-938.
11. Lippi G, Sanchis-Gomar F, Cervellin G. Global Epidemiology Of Atrial Fibrillation: An Ğnc-reasing Epidemic And Public Health Challenge. *International Journal of Stroke*, 2021; 16(2): 217-221.
12. Uyarel H, Onat A, Yüksel H, et al. Türk halkında kronik atriyal fibrilasyon insidansı, prevalansı vemortalitesine ilişkin tahminler. *Türk Kardiyoloji Derneđi Arşivi*. 2008; 36(4): 214-22.
13. Sarı C, Köseoglu C, Ayhan H. Atriyal Fibrilasyon Tedavisinde Güncel Yaklaşımlar/Current Approaches In Atrial Fibrillation Treatment. *Dicle Tip Dergisi*, 2014; 41(3): 614.
14. Şengül Ş, Uysal H. Atriyal Fibrilasyon Tanısı Olan Hastalarda Obstrüktif Uyku Apnesi ve Uyku Kalitesinin Belirlenmesi. *Turk J Cardiovasc Nurs*, 2019; 10(22): 50-58.
15. Yavuz B, Ata N, Oto E, et al. Demographics, treatment and outcomes of atrial fibrillation in a developing country: the population-based Turkish Atrial Fibrillation (TRAF) cohort. *Europace*. 2017; 19(5): 734-40.
16. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. *Circulation*. 2003; 107(23): 2920-5.
17. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *Jama*. 2001; 285(18): 2370-5.
18. Garson Jr A, et al. Atrial flutter in the young: a collaborative study of 380 cases. *Journal of the American College of Cardiology*, 1985; 6(4): 871-878.
19. Kannel W.B, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. *New England Journal of Medicine*, 1982; 306(17): 1018-1022.
20. Won C.-K, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. *American heart journal*, 2000; 140(6): 878-885.
21. Diker E, et al. Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease. *The American journal of cardiology*, 1996; 77(1): 96-98.
22. Griffin B, P Topo, E. J. Nair D, et al. *Manual of cardiovascular medicine*. Lippincott Williams & Wilkins. 2008.

23. Granada J, et al. Incidence and predictors of atrial flutter in the general population. *Journal of the American College of Cardiology*, 2000; 36(7): 2242-2246.
24. Lip GYH, Watson T. Atrial fibrillation (acute onset). *Clin Evid* 2006; 15: 1-3.
25. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology*. 2016; 18(11): 1609-78.
26. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ ACC/HRS Guideline for the management of patients with atrial fibrillation. *Circulation* 2019;140: 125-151.
27. McCabe PJ, Rhudy LM, DeVon HA. Patients' experiences from symptom onset to initial treatment for atrial fibrillation. *J Clin Nurs* 2015; 24: 786-796.
28. Rienstra M, Vermond RA, Crijns HJ, et al. RACE Investigators. Asymptomatic persistent atrial fibrillation and outcome: results of the RACE study. *Heart Rhythm* 2014; 11: 939-945.
29. Fengler BT, Bradt WJ, Plautz CU. Atrial fibrillation in the Wolff-Parkinson-White syndrome: ECG recognition and treatment in the ED. *Am J Emerg Med*. 2007; 25(5): 576-583.
30. Bano A, et al. Association of Diabetes With Atrial Fibrillation Phenotype and Cardiac and Neurological Comorbidities: Insights From the Swiss AF Study. *Journal of the American Heart Association*, 2021: 10(22); p. e021800.
31. Echouffo-Tcheugui J.B, et al. Care patterns and outcomes in atrial fibrillation patients with and without diabetes: ORBIT-AF registry. *Journal of the American College of Cardiology*, 2017; 70(11): 1325-1335.
32. Karcioğlu O. Kardiyovasküler Aciller ve İleri Yaşam Desteği. İstanbul: Ema Kitap Evi; 2021.
33. Groenveld HF, Crijns HJ, Van den Berg MP, et al. RACE II Investigators. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. *J Am Coll Cardiol* 2011; 58: 1795-1803.
34. Van Gelder IC, Wyse DG, Chandler ML, et al. RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. *Europace* 2006; 8: 935-942.
35. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. *The American journal of medicine*. 2003; 114(1): 51-5.
36. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. *The New England journal of medicine*. 2010; 362(15): 1363-73.
37. Piccini JP, Fauchier L. Rhythm control in atrial fibrillation. *Lancet (London, England)*. 2016; 388(10046): 829-40.
38. Van Gelder IC, Rienstra M, Crijns HJ, et al. Rate control in atrial fibrillation. *Lancet* 2016; 388: 818-828.
39. Turakhia MP, Santangeli P, Winkelmayr WC, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. *J Am Coll Cardiol* 2014; 64: 660-668.
40. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among patients taking digoxin analysis from the AFFIRM study. *Eur Heart J* 2013; 34: 1481-1488.
41. Clemons HF, Wood MA, Gilligan DM, et al. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. *Am J Cardiol* 1998; 81: 594-598.
42. Crawford M.H. "Current Diagnosis And Treatment" Serisi. (Ç. Erol. Çev. Ed.) Ankara: Güneş Tıp Kitabevleri, 2017; 141-149.
43. Bennett D.H. Kardiyak Aritmiler Tanı Ve Tedavi İçin Pratik Notlar. (M. Kanadacı. Çev.) Ankara: Nobel Kitabevi, 2008; 33-49.
44. Dan GA, Martinez-Rubio A, Agewall S, et al. ESC Scientific Document Group. Antiarrhythmic

- drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology. *Europace* 2018; 20: 731-732.
45. Conti A, Del Taglia B, Mariannini Y, et al. Management of patients with acute atrial fibrillation in the ED. *Am J Emerg Med.* 2010; 28(8): 903-910
 46. Atriyal Fibrilasyon Tedavisi ESC Kılavuzunun 2012 Odaklı Güncellemesi. *Türk Kardiyoloji Derneği Arş.* 2013; 41(3): 53-81.
 47. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. *Circulation.* 2005; 112(12): 1687-91.
 48. Heckman GA, Braceland B. Integrating frailty assessment into cardiovascular decision making. *Canadian Journal of Cardiology.* 2016; 32(2): 139-41.
 49. Cerdá M, Cerezo-Manchado JJ, Johansson E, et al. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. *Journal of comparative effectiveness research.* 2019; 8(3): 165-78.
 50. Vermond RA, Crijns HJ, Tijssen JG, et al. RACE II investigators. Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. *Europace* 2014;16: 1417-1425.
 51. Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010; 138: 1093-1100.